Andrew M Haydon

9PUBLICATIONS
86CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)ChemotherapyEpidemiological methods
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jan 09, 2026
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial.

Timothy Iveson, Mark P Saunders, Caroline Kelly

|Jan 05, 2026
Incidence of Reported Pseudoprogression on 18F-FDG PET/CT in Metastatic Melanoma Patients Undergoing Immune Checkpoint Inhibitor Immunotherapy.

Philip Macilwraith, Mark Shackleton, Andrew Haydon

|Sep 26, 2022
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).

Jeffrey S Weber, Dirk Schadendorf, Michele Del Vecchio

|Aug 23, 2022
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.

Jason A Chesney, Antoni Ribas, Georgina V Long

|Jun 28, 2022
Non-aspirin non-steroidal anti-inflammatory drugs in colorectal cancer: a review of clinical studies.

Farzana Y Zaman, Suzanne G Orchard, Andrew Haydon

|Apr 08, 2022
Effect of Aspirin on Melanoma Incidence in Older Persons: Extended Follow-up of a Large Randomized Double-blind Placebo-controlled Trial.

Mabel K Yan, Suzanne G Orchard, Nikki R Adler

Pageof 2

Frequent Collaborators

3 joint publications

Ralf Gutzmer

2 joint publications

Piotr Rutkowski

2 joint publications

Jean-Jacques Grob

2 joint publications

James Larkin